UNITED ~~STATES SECURITIES~~STATESSECURITIES AND EXCHANGE ~~COMMISSION~~ ~~Washington~~COMMISSIONWashington, DC ~~20549 FORM~~20549FORM 8-KKCURRENT ~~CURRENT~~REPORTPursuant ~~REPORT Pursuant~~ to Section 13 OR 15(d) of the Securities Exchange Act of ~~1934~~ ~~June~~1934July 418, ~~2003 Date~~2003Date of Report (Date of earliest event reported) ~~AMERICAN~~NANOBAC ~~ENTERPRISE~~PHARMACEUTICALS, ~~CORPORATION~~ INCORPORATED(Exact name of registrant as specified in its charter)

Florida 0-24696 59-3248917 (State of other jurisdiction Commission File RS Employer of incorporation Number Identification No.

~~525~~5025 West Lemon Street, Tampa, ~~Florida~~ ~~33609~~Florida 33609(Address of principal executive offices) (Zip Code) (813)-287-~~9733 Registrant~~9733Registrant's telephone number, including area code

Item 25: ~~Acquisition~~Other orEvents ~~Disposition~~Effective ofJuly ~~Assets: An acquisition of the majority ownership of NanobacLabs Pharmaceuticals~~21, ~~Inc. ("Nanobac") was completed by American Enterprise Corporation (the "Company" or "AMER") partially on June 2 concluding on June 4,~~ 2003~~. On June 4~~, ~~2003, the Company acquired 6,100,000 shares from Doctor Gary S. Mezo and Mrs. Nancy M. Schriewer-Mezo representing approximately 74.4% of~~ Nanobac inPharmaceuticals ~~exchange~~will ~~for 24,400,000~~trade ~~restricted~~under ~~AMER no par value common shares together with a loan in~~ the ~~amount of $300,000 and a commitment to provide additional~~symbol ~~equity capital during the twelve months following the acquisition~~"NNBT. Together with the 37,650,395 AMER no par value common shares previously issued, as of June 4, 2003, the Company has 62,050,395 no par value common shares issued and outstanding. Dr. Mezo is Chairman of Nanobac's Board of Directors. In addition, the Company has agreed to acquire the remaining 2,089,500 outstanding shares of Nanobac for 8,358,000 AMER shares and, if exercised, 500,000 options to acquire Nanobac shares for 2,000,000 AMER shares. The option holder is not obligated to exercise its option. "

In The ~~the~~Company ~~event all~~previously ~~Nanobac~~announced ~~shares are converted, AMER will have issued an aggregate of 34,758,000 shares and shall have issued and outstanding~~ a ~~total of 72,408,395~~ ~~shares. In~~name ~~such~~change anfrom ~~event,~~American ~~the~~Enterprise ~~owners~~Corporation ofto Nanobac ~~will own approximately 48% of AMER. About Nanobac NanobacLabs~~ Pharmaceuticals, Inc. ~~is a research-oriented~~ ~~specialty~~following ~~pharmaceutical company dedicated to~~ the ~~development~~acquisition of ~~innovative prescription~~NanobacLab ~~nanobiotics(R)~~Pharmaceutical, medical diagnostics, medical nanotechnology and nanobiotechnologies NanobacLabs has developed the nanobiotics(R), NanobacTX(R) (heart disease and atherosclerosis), UroBac(R) (urology) and DermaBac(R) (dermatology), which are patent-pending prescription compounds targeted to treat nanobacterial infections in humansInc. ~~NanobacLabs' nanobiotics~~(~~R) are the only treatments for nanobacterial infections.~~ NanobacLabs ~~has additional nanobiotics(R~~) inthrough ~~its development pipeline. NanobacLabs' researchers have developed~~ a ~~blood~~common ~~test~~stock ~~(NanobacTEST-S(R))~~share ~~for nanobacterial antigen and IgG antibodies as well as a rapid urine-screening test for nanobacterial antigen (NanobacTEST-U/A(R))~~exchange. ~~For more information on NanobacLabs research, diagnostics and nanobiotics(R), visit the website at http://www.NanobacLabs.com Item 5: Other Events and Regulation FD Disclosure~~

About Nanobac ~~Effective~~NanobacLabs Pharmaceuticals, ~~June~~Inc. ~~20,~~is ~~2003,~~a ~~the~~research-oriented ~~Company~~specialty pharmaceutical company ~~changed~~dedicated ~~its~~to ~~name~~the ~~from~~development ~~American~~of ~~Enterprise~~innovative ~~Corporation~~prescription tonanobiotics(R), ~~Nanobac~~medical ~~Pharmaceuticals~~diagnostics, ~~Incorporated.~~ medical nanotechnology and nanobiotechnologies NanobacLabs has developed the ~~Item~~nanobiotics(R), 7:NanobacTX(R) ~~Financial~~(heart ~~Statements~~disease and ~~Exhibits~~atherosclerosis), UroBac(R) a.(urology) ~~The~~and ~~Company~~DermaBac(R) ~~undertakes~~(dermatology), towhich ~~file~~are ~~required~~patent-pending prescription ~~financial~~compounds ~~statements~~targeted onto ortreat ~~before~~nanobacterial ~~sixty~~infections ~~days~~in ~~following~~humans. ~~this~~NanobacLabs' nanobiotics(R) ~~Form~~are ~~8-K~~the only treatments for nanobacterial infections. NanobacLabs bhas ~~The~~additional ~~Company~~nanobiotics(R) ~~includes~~in asits ~~Exhibit~~development 99pipeline.1 NanobacLabs' aresearchers ~~Press Release~~have ~~issued~~developed ~~May~~a ~~29,~~blood ~~2003~~test c(NanobacTEST-S(R)) ~~The~~for ~~Company~~nanobacterial ~~includes~~antigen and IgG antibodies as ~~Exhibit~~well ~~99.2~~as a rapid ~~Press~~urine-screening test for nanobacterial antigen (NanobacTEST-U/A(R)). ~~Release~~ For ~~issued~~more ~~June~~information 2,on ~~2003~~NanobacLabs research, ~~Item~~diagnostics 9:and ~~Regulation~~nanobiotics(R), FDvisit ~~Disclosure~~the website at http://www.NanobacLabs.comItem 7: Financial ~~The~~Statements ~~Company~~and ~~has~~Exhibits a. ~~made~~The ~~two~~company issued ~~public~~a ~~announcements~~press release relating to the ~~acquisition~~ ofnew ~~Nanobac~~trading symbol. A ~~Both~~copy ~~press~~of ~~releases~~the release ~~are~~is attached ~~hereto~~ as ~~Exhibits~~Exhibit 99.~~1 and 99.2.~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

~~AMERICAN~~NANOBAC ~~ENTERPRISE~~PHARMACEUTICALS, ~~CORPORATION~~ INC.(Registrant) Date ~~June~~July 1918, ~~2003 S~~2003S/S JOHN ~~STANTON~~ ~~John~~STANTONJohn ~~Stanton Chief~~StantonChief Executive ~~Officer~~ Officer

Filing Compare · NANOBAC PHARMACEUTICALS INC